China Patent for Therapeutic Vaccine Treatment of Obesity to be Granted to Braasch Biotech
China's State Intellectual Property Office to grant Braasch Biotech's patent on Therapeutic treatment of human and pet obesity.
Garretson, SD, March 13, 2015 --(PR.com)-- Braasch Biotech LLC, a biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced the company has been notified by China’s State Intellectual Property Office (SIPO) concerning the office’s approval of a patent application, Compositions and Methods for Enhanced Somatostatin Immunogenicity.
The patent utilizes Braasch Biotech’s Cross-Platform TechnologyTM for treatment of phenotypic obesity in humans, dogs and cats. By utilization of a single conserved mammalian target (somatostatin 14), Braasch is able to utilize a similar vaccine composition for multiple species and applications.
Human Obesity in China
The percentage of Chinese adults who are overweight and obese rose from 25 percent in 2002 to 38.5 percent in 2010 in a population of 1.37 billion, according to the World Health Organization. WHO projects that 50 to 57 percent of the Chinese population will be overweight or obese by the end of 2015.
In China, the obesity problem is primarily an urban one in a population that is rapidly urbanizing. Obesity tends to be an issue that grows along with affluence. With increased prosperity comes the ability to eat more meat, fast foods and bigger meals. At the same time, a sedentary working regime with long hours at a desk or factory jobs equates to less physical activity.
Canine Obesity in China
As is the case with many other cultures, when human obesity rates increase there is an associated increase in canine obesity. In 2013, Mao et al published the first epidemiological report on canine obesity in China in the Journal of Preventive Veterinary Medicine. Their survey, from 14 animal hospitals over a three-year period, concludes the overall canine obesity rate in Beijing was 44.4%.
“We are very pleased that the Chinese SIPO has recognized the Braasch’s vaccine novelty and commercial utility in the fight against human and pet obesity,” stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. “ Additional patent applications for the our therapeutic obesity technologies are issued or pending in a number of other countries including the US, Europe, Mexico, South Africa, Brazil, Canada, India, Japan and Korea.
About Braasch Biotech
Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota. The company is pioneering a new field of therapeutic approaches utilizing Somatovac® vaccine technologies.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256
jeralyn@braaschbiotech.com
The patent utilizes Braasch Biotech’s Cross-Platform TechnologyTM for treatment of phenotypic obesity in humans, dogs and cats. By utilization of a single conserved mammalian target (somatostatin 14), Braasch is able to utilize a similar vaccine composition for multiple species and applications.
Human Obesity in China
The percentage of Chinese adults who are overweight and obese rose from 25 percent in 2002 to 38.5 percent in 2010 in a population of 1.37 billion, according to the World Health Organization. WHO projects that 50 to 57 percent of the Chinese population will be overweight or obese by the end of 2015.
In China, the obesity problem is primarily an urban one in a population that is rapidly urbanizing. Obesity tends to be an issue that grows along with affluence. With increased prosperity comes the ability to eat more meat, fast foods and bigger meals. At the same time, a sedentary working regime with long hours at a desk or factory jobs equates to less physical activity.
Canine Obesity in China
As is the case with many other cultures, when human obesity rates increase there is an associated increase in canine obesity. In 2013, Mao et al published the first epidemiological report on canine obesity in China in the Journal of Preventive Veterinary Medicine. Their survey, from 14 animal hospitals over a three-year period, concludes the overall canine obesity rate in Beijing was 44.4%.
“We are very pleased that the Chinese SIPO has recognized the Braasch’s vaccine novelty and commercial utility in the fight against human and pet obesity,” stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. “ Additional patent applications for the our therapeutic obesity technologies are issued or pending in a number of other countries including the US, Europe, Mexico, South Africa, Brazil, Canada, India, Japan and Korea.
About Braasch Biotech
Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota. The company is pioneering a new field of therapeutic approaches utilizing Somatovac® vaccine technologies.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256
jeralyn@braaschbiotech.com
Contact
Braasch Biotech LLC
Keith Haffer
605-376-8756
www.braaschbiotech.com
Keith Haffer
605-376-8756
www.braaschbiotech.com
Contact
Categories